| Document |
Document Title |
|
WO/2019/080227A1 |
The present invention relates to the technical field of pesticides, and in particular to a substituted benzoyl isoxazole compound or a tautomer and a salt thereof, a preparation method, a herbicide composition and an application. The sub...
|
|
WO/2019/081485A1 |
The invention relates to substituted pyrazoles of general formula (I) or salts thereof, wherein the groups of general formula (I) are defined as cited in the description, and to the use thereof as herbicides, in particular for controllin...
|
|
WO/2019/079632A1 |
Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are me...
|
|
WO/2019/016781A1 |
Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and use thereof for prevention and/or treatment of microbial infections and/or related diseases or conditions. The ...
|
|
WO/2019/016782A1 |
Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and use thereof for prevention and/or treatment of microbial infections and/or related diseases or conditions. The ...
|
|
WO/2018/202654A1 |
The present invention relates to a process for preparing optically active compounds of formula X and intermediates thereof, (formula X) wherein the variables of compound of formula X are as defined in the claims and the description.
|
|
WO/2018/177970A1 |
The present invention relates to pyrimidinium compounds of formula (I), to the stereoisomers, salts, tautomers and N-oxides thereof, their mixtures and to compositions comprising such compounds or mixtures. The invention also relates to ...
|
|
WO/2018/166934A1 |
The present invention relates to dibenzofuran and dibenzothiophene derivatives, in particular for use as triplet matrix materials in organic electroluminescent devices. The invention further relates to a method for producing the compound...
|
|
WO/2018/114596A1 |
The invention relates to substituted heteroaryl pyrrolones of general formula (I) and salts thereof, wherein the groups of general formula (I) are defined as cited in the description, and to the use thereof as herbicides, in particular f...
|
|
WO/2018/109649A1 |
The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and...
|
|
WO/2018/109642A1 |
The present invention relates to N-aryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators. In particular, the compounds of this invention include a compound of Formul...
|
|
WO/2018/019574A1 |
The present invention relates to the pyrimidine compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, use of pyrimidine compounds ...
|
|
WO/2018/014829A1 |
The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossif...
|
|
WO/2018/007323A1 |
The present disclosure relates to fungicidal active compounds of formula (I), more specifically to benzosultams and analogues thereof, processes and, intermediates for their preparation and use thereof as fungicidal active compound, part...
|
|
WO/2017/153234A1 |
The invention relates to new substituted N-Cyclo-2-aryl-quinoline-4-carboxamide derivatives, to methods for the production thereof, to the use thereof either alone or in combination for treating and/or preventing diseases and to their us...
|
|
WO/2017/147526A1 |
Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathoge...
|
|
WO/2017/099516A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present disclosure is capable of producing an...
|
|
WO/2017/096472A1 |
Cephem compounds, pharmaceutically acceptable salts thereof, and methods of using same, wherein the compound has a bicyclic nitrogen-containing aromatic heterocyclic ring as the quaternary ammoniomethyl group at the 3-position and one or...
|
|
WO/2017/092473A1 |
Provided are a compound with connected indole heterocycles, and a mixture, a composition, an organic electronic device containing the compound, and a use. In certain preferred embodiments, the hydrogen atom in a C-H bond on a indolocarba...
|
|
WO/2017/044571A1 |
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus : The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP...
|
|
WO/2016/180537A1 |
The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
|
|
WO/2015/196258A1 |
The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosur...
|
|
WO/2015/134210A1 |
The present disclosure is directed to certain inhibitors of RLK and ITK of formula (I), pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by inhibition of RLK and ITK.
|
|
WO/2015/134039A1 |
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.
|
|
WO/2015/117912A1 |
Compounds of formula (I), wherein (II) is a five-membered, aromatic ring system which may contain 2 or 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur,and where each ring system may not contain more than ...
|
|
WO/2015/104677A1 |
The present invention provides a compound of formula I, or an isotopic form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparati...
|
|
WO/2015/075174A1 |
The present invention relates to N-acylimino compound of formula (I): wherein X is O or S, in particular O; Y is a single bond, O, S or NR5; Het is a 5 or 6 membered carbon-bound or nitrogen-bound heterocyclic ring, W1-W2-W3-W4 represent...
|
|
WO/2015/042414A1 |
The invention generally relates to compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use...
|
|
WO/2014/172190A1 |
Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein A is a radical selected from the group consisting of A-1 through A-11, L is C(R12a)R12b-C(R13a)R13b; or 1,2-phenylene G is a radical ...
|
|
WO/2014/152588A1 |
Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
|
|
WO/2014/128022A1 |
Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of statins.
|
|
WO/2014/086712A1 |
The present invention relates to compounds of general formula I, wherein the groups (Het)Ar and R1 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activ...
|
|
WO/2014/063929A1 |
The present invention relates to substituted pyrazoles of formula (I) wherein the variables have the meaning as defined in the description, combinations of these compounds and other pesticides, methods and use of these compounds and comb...
|
|
WO/2014/057435A1 |
The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically ac...
|
|
WO/2014/047707A1 |
The present invention relates to a compound of formula (I) or to a pharmaceutically acceptable salt thereof with analgesic activity. In particular, the compounds according to the present invention are useful for treating or preventing ac...
|
|
WO/2013/135674A1 |
The present invention provides compound of formula I (I) wherein A1 is C-R5b; A2, A3 and A4 are independently of one another C-H or C-R5a, or nitrogen; G1 is oxygen; Y1--Y2-Y3 is -C=N-0-; X1 is halogen; X2 is hydrogen, or halogen; R3 is ...
|
|
WO/2013/098229A2 |
The invention relates to heteroarylpiperidine and piperazine derivatives of formula (I) in which the symbols RA1, RA2, X, Y, L1, L2, RB1, RB2, G, Q, p, R1, R2 and R10 have the meanings indicated in the description, as well as to salts, m...
|
|
WO/2013/006485A1 |
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...
|
|
WO/2012/173682A2 |
The invention relates to compounds of Formula I pharmaceutically acceptable salt, ester or prodrug thereof:
|
|
WO/2012/153775A1 |
Provided is an anticancer agent which has an Ras function inhibitory effect. The present invention provides an Ras function inhibitor which contains a compound represented by formula (I') (wherein the symbols are as defined in the descri...
|
|
WO/2012/130306A1 |
The present invention provides novel 2,3-dihydrobenzazine compounds of formula (I) and to their salts. The compounds inhibit cell proliferation and cell division and they also inhibit the activation of Hypoxia Inducible Factor (HIF)-medi...
|
|
WO/2012/120055A1 |
The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.
|
|
WO/2012/120050A1 |
The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
|
|
WO/2012/120058A1 |
The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
|
|
WO/2012/120057A1 |
The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
|
|
WO/2012/120056A1 |
The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
|
|
WO/2012/120135A1 |
The invention relates to new isoxazoline compounds of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compo...
|
|
WO/2012/102255A1 |
The present invention provides a compound represented by general formula (I) (in the formula: A is a benzene ring, pyridine ring, or the like; Y1 is an alkylene group having 1-6 carbon atoms, or the like; Y2 is a single bond or the like;...
|
|
WO/2012/098049A1 |
The present invention relates to a process for the preparation of statins by means of a Julia-Kocienski reaction between an aldehyde and a sulfone derivative in the presence of an alkaline metal alkoxy base. The resulting derivatives are...
|
|
WO/2012/098050A1 |
The present invention relates to a process for the preparation of a 1-methyl-1H-tetrazole-5-thio derivative comprising reaction of a halomethyl substrate with 1-methyl-H-tetrazole-5-thiol to obtain a thio-ether compound, and oxidizing th...
|
